A recent study that looked back at 21 FDA oncology drug approvals from 2015 to 2018 showed that clinical trials conducted primarily outside the U.S. were half as likely to enroll Black participants as trials in the U.S.

Black patients accounted for 3.2 percent of overall enrollment and 5 percent of enrollment in the U.S. Looking at 10,318 patients in those trials, 3,713 participants (36 percent) were enrolled in the U.S. with the remainder from outside the U.S.

The findings were published in the March 8, 2021, issue of the American Cancer Society’s peer-reviewed journal, Cancer.